PCVX Q3 2024 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$140M

Net Income

-$103M

EPS (Diluted)

$-0.83

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$99M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$3.6B

Total Liabilities

$142M

Stockholders' Equity

$3.4B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$140M	-$113M	-23.8%
Net Income	-$103M	-$93M	-11.3%